Close Menu

GSK

The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.

The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.

With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.

Partnered Up

Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.

The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

Pages

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.